PODXL2

Across TCGA pan-cancer cohorts, PODXL2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PODXL2 data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PODXL2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PODXL2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and GBM show a favorable association.

LUAD, GBM, and HNSC are the cancer types where PODXL2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	All	1.000	0.274	.015	14	view →
GBM	DFS	Tertile	All	0.839	0.645	.002	9	view →
HNSC	DFS	Median	II,III,IV	0.890	1.000	.014	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

PODXL2–LUAD (OS)

Open the LUAD breakdown →